Q/C TECHNOLOGIES, INC. QCLS
Technologies, Inc. (the "Company") has historically been engaged in the development and commercialization of therapeutic
platforms based on well-defined biological targets, including Isomyosamine and Supera-CBD. More recently, the Company has shifted
its business strategy to focus on energy-efficient blockchain and cryptocurrency infrastructure through quantum-class laser-based
computing.
Last close
0.47
2026-10-23
Market cap
$3.9M
2026-06-30 share count
52-week range
0.42 - 8.17
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-8.66
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $1.6M | $1.7M | $3.4M | $3.0M |
| Cost of revenue | — | — | — | — | — | — | $46.5K | $93.6K | $136.1K | $138.7K |
| Gross profit | — | — | — | — | — | — | $478.7K | $127.3K | $948.6K | $1.9M |
| R&D | $3.5M | $3.4M | $7.9M | $9.1M | $6.7M | $2.5M | $276.8K | $1.1M | $1.3M | $1.2M |
| SG&A | $3.7M | $4.2M | $5.4M | $5.5M | $6.4M | $2.9M | $3.4M | $5.7M | $4.1M | $3.0M |
| Operating income | -$9.8M | -$10.2M | -$17.1M | -$15.3M | -$28.8M | -$9.5M | -$3.5M | -$10.1M | -$6.6M | -$3.3M |
| Pre-tax income | -$11.6M | -$23.4M | -$4.0M | -$15.2M | -$29.9M | -$9.5M | -$3.4M | -$10.8M | -$7.4M | -$3.3M |
| Net income | -$11.6M | -$23.4M | -$4.0M | -$15.2M | -$29.9M | -$9.5M | -$3.9M | -$10.8M | -$7.4M | -$3.3M |
| EPS, basic | -8.66 | -1,080.87 | -5.33 | -11.74 | -0.85 | — | — | — | — | — |
| EPS, diluted | -8.66 | -1,080.87 | -5.33 | -11.74 | — | -2.49 | -6.35 | -22.28 | -6.29 | -0.61 |
| Shares, diluted (wtd. avg.) | 1.7M | 25,129 | 1.5M | 1.3M | 35.0M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $987.0K | $173.2K | $2.7M | $749.1K | $556.0K | $148.3K | $517.4K | $181.8K | $438.4K | $72.7K |
| Short-term investments | $14.8M | $8.3M | $2.2M | $4.1M | $11.0M | $16.7M | $9.2M | $5.3M | $5.0M | $50.0K |
| Receivables | — | — | — | — | — | — | $42.9K | $176.3K | $964.7K | $601.3K |
| Inventory | — | — | — | — | — | $197.7K | $199.0K | $585.3K | $947.6K | $2.0M |
| Total current assets | $16.6M | $9.4M | $5.8M | $5.4M | $12.7M | $149.5K | $10.3M | $6.7M | $7.8M | $3.2M |
| Property, plant and equipment | — | — | — | — | — | — | $33.6K | $83.5K | $235.1K | $259.4K |
| Goodwill | $10.5M | $10.5M | $10.5M | $10.5M | $10.5M | — | — | — | — | — |
| Other intangibles | $14.1M | — | — | — | — | — | $170.4K | $243.4K | $1.1M | $1.3M |
| Total assets | $41.2M | $21.4M | $17.9M | $17.5M | $24.8M | $676.7K | $10.9M | $7.8M | $9.3M | $5.1M |
| Accounts payable | $2.4M | $2.9M | $3.7M | $2.7M | $986.6K | $1.1M | $891.9K | $2.0M | $1.8M | $1.5M |
| Total current liabilities | $5.5M | $6.7M | $5.0M | $2.8M | $1.0M | $2.3M | $1.5M | $2.0M | $1.8M | $1.7M |
| Total liabilities | $16.4M | $6.7M | $5.1M | $2.8M | $1.2M | $5.9M | $1.5M | $2.0M | $1.8M | $1.7M |
| Retained earnings | -$144.1M | -$129.1M | -$102.0M | -$93.8M | -$78.6M | -$48.7M | -$119.6M | -$115.7M | -$104.8M | -$97.5M |
| Total equity | $21.8M | $9.8M | $12.4M | $14.7M | $23.6M | -$5.3M | -$2.3M | $5.8M | $7.6M | $3.4M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$9.1M | -$9.0M | -$13.0M | -$12.3M | -$19.5M | -$4.7M | -$3.1M | -$8.5M | -$5.1M | -$4.2M |
| Depreciation and amortisation | — | — | — | — | — | $29.5K | $74.1K | $234.5K | $249.9K | $286.2K |
| Stock-based compensation | $2.2M | $1.1M | $3.0M | $695.2K | — | $855.0K | $10.8K | $12.5K | $5.5K | $51.7K |
| Capital expenditure | $1.8M | — | — | — | — | — | — | $68.2K | $54.5K | $123.3K |
| Investing cash flow | -$8.4M | -$6.1M | $1.8M | $6.9M | $19.9M | -$8.8M | -$3.9M | -$359.7K | -$5.0M | $3.8M |
| Financing cash flow | $18.3M | $12.6M | $13.1M | $5.6M | $73.5K | $4.7M | $7.0M | $9.1M | $10.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-019663.
Plot the figures US dollars
Income statement
Revenue
Cost of revenue
Gross profit
R&D
SG&A
Total operating expenses
Operating income
Interest expense
Pre-tax income
Income tax
Net income
EPS, basic
EPS, diluted
Shares, diluted (wtd. avg.)
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $3.4M | $1.7M | $1.6M | — | — | — | — | — | — |
| Gross profit | $1.9M | $948.6K | $127.3K | $478.7K | — | — | — | — | — | — |
| Net income | -$3.3M | -$7.4M | -$10.8M | -$3.9M | -$9.5M | -$29.9M | -$15.2M | -$4.0M | -$23.4M | -$11.6M |
Recent filings and events
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Other event Item 8.01
- Material agreement signed Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event Item 8.01
- Officer or director change Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2835
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| IDXX | IDEXX LABORATORIES INC /DE | $44.15B | 42.8x | 10.4% |
| LNTH | Lantheus Holdings, Inc. | $6.51B | 29.3x | 0.5% |
| NEOG | NEOGEN CORP | $2.66B | — | -2.7% |
| CLDX | Celldex Therapeutics, Inc. | $2.30B | — | -78.0% |
| NTLA | Intellia Therapeutics, Inc. | $1.57B | — | 16.9% |
| QDEL | QuidelOrtho Corp | $941.5M | — | -1.9% |
| ACHV | ACHIEVE LIFE SCIENCES, INC. | $667.8M | — | — |
| MYGN | MYRIAD GENETICS INC | $556.7M | — | -1.6% |